Pfizer Inc. $PFE Stake Raised by Morningstar Investment Management LLC

by · The Cerbat Gem

Morningstar Investment Management LLC boosted its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 19.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 57,082 shares of the biopharmaceutical company’s stock after acquiring an additional 9,270 shares during the quarter. Morningstar Investment Management LLC’s holdings in Pfizer were worth $1,384,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Capital Advisory Group Advisory Services LLC raised its holdings in Pfizer by 2.9% during the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock worth $328,000 after buying an additional 388 shares during the period. Citizens National Bank Trust Department raised its holdings in Pfizer by 0.9% during the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock worth $1,118,000 after buying an additional 395 shares during the period. Trust Co of the South raised its holdings in Pfizer by 1.5% during the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock worth $712,000 after buying an additional 441 shares during the period. Charter Oak Capital Management LLC raised its holdings in Pfizer by 4.3% during the 2nd quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company’s stock worth $258,000 after buying an additional 444 shares during the period. Finally, Ballentine Partners LLC raised its holdings in Pfizer by 0.5% during the 2nd quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company’s stock worth $2,260,000 after buying an additional 458 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

Shares of NYSE PFE opened at $24.72 on Tuesday. The business has a fifty day simple moving average of $24.88 and a 200 day simple moving average of $24.12. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $140.52 billion, a price-to-earnings ratio of 13.15, a PEG ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.82.

Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the company posted $0.60 earnings per share. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is currently 91.49%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on PFE shares. Bank of America boosted their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Citigroup upped their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. UBS Group reiterated a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average target price of $28.35.

Get Our Latest Analysis on PFE

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).